Etiket: Children

OBJECTIVE:

The aim of this study was to assess the anxiety and depression symptom severity in a group of epileptic children and compare the results to healthy controls. Additionally, the frequency of psychiatric disorders in epileptic children was also assessed.

METHOD:

The study compared 30 children, ranging in age from 8 to 16 years with epileptic disorder who attended a children’s neurology clinic, with healthy controls using the State-Trait Anxiety Inventory and Children’s Depression Inventory scores and suicidal ideation. The MINI was administered to epileptic patients to determine the frequency of psychiatric disorders in this clinical group.

RESULTS:

State anxiety scores of the epilepsy group were significantly higher compared to controls. No significant differences were found between patients and controls in terms of trait anxiety and depression scores. In all 3 scales boys scored significantly higher than girls. No significant relationships were found between symptom severity, duration of epilepsy, age of seizure onset and depression and anxiety scores. Psychiatric assessments with the MINI identified psychiatric disorders in 26.7% of epileptic patients. Two epileptic patients reported past suicidal attempts however, only 2 patients were receiving psychiatric treatment.

CONCLUSION:

Psychiatric disorders were frequently observed in the group of epileptic patients. Psychiatric disorders occurred more frequently in boys compared to girls in this group. Clinicians should be more aware of accompanying psychiatric symptoms in epileptic patients and take the necessary precautions in the early period of the illness in an effort to prevent future mental health problems.

OBJECTIVE:

The present study aimed to determine the rate of treatment compliance in children with attention deficit hyperactivity disorder (ADHD) that were newly prescribed methylphenidate, and to evaluate the associated clinical and sociodemographic factors, as well as parental concerns about drug treatment.

METHOD:

The sample of this prospective and observational study consisted of 238 children aged 7-18 years with ADHD diagnosed according to DSM-IV criteria. At the end of the first year, the study sample was splitted into 2 groups; compliant and non-compliant. Parental attitudes toward drug therapy, and clinical and sociodemographic characteristics of the 2 groups were compared. A clinician rated parental concerns about drug treatment 4-6 weeks after the interview that was conducted in order to inform them about methylphenidate therapy. Regarding a minimum requirement of 5 days weekly dosage and drug holidays, cases that took more than 70% of the recommended methylphenidate dose at the end of the first year were described as compliant.

RESULTS:

At the end of the first year of treatment, the drug compliance rate was 80.3% (n= 191). The non-compliant group consisted of older children. A significant difference was observed between the compliant and non-compliant groups in terms of parental approach toward drug treatment. Children in the non-compliant group had parents that had doubts about pharmacotherapy and these children were less compliant with methylphenidate treatment.

CONCLUSION:

Parental concerns about methylphenidate treatment in ADHD may influence treatment compliance. Additionally, it is suggested that developmental psychological characteristics associated with adolescence may also be important.

Information about the relationship between psoriasis and psychiatric morbidity and quality of life in children and adolescents is limited. We aimed to examine the symptoms of depression and anxiety and health-related quality of life levels in children and adolescents with psoriasis. Forty-eight outpatients with psoriasis aged 8 to 18 years are included in this study. Child Depression Inventory (CDI), State-Trait Anxiety Inventories for Children (STAI-C) and Pediatric Quality of Life Inventory Parent and Child Versions (PedQL-P and C) were applied to both patient and control groups. Psoriasis symptom severity was measured by the Psoriasis Area Severity Index (PASI). Both study and control groups were divided into two age groups, child (8-12 yrs) and adolescent (13-18 yrs), to exclude the effect of puberty on psychological condition. The mean CDI score was higher, and PedQL-C psychosocial and total scores were lower in the children compared with controls. Duration of psoriasis had an increasing effect on physical-health and total scores of PedQL-C in the child group and all PedQL-C scores in the entire sample. Psoriasis severity showed a negative correlation with psychosocial and total scores of PedQL-P in the adolescent group and PedQL-P physical-health scores in the entire sample. Psoriasis is related to depression and impaired quality of life in children. The depressive symptoms in children with psoriasis should not be overlooked and psychiatric assessment of these children should be provided.